glp 1 and perimenopause Are you navigating menopause while considering GLP-1 treatments? You're not alone in having questions. With so much conflicting information out there, it's crucial to distinguish between myths evidence-based facts. From hormone GLP-1 Microdosing for Perimenopause and
Description
Hathaway JT, Shah MP, Hathaway DB, et al

Most patients experience only mild gastrointestinal side effects, such as nausea or constipation, which often decrease as the body adjusts

Patients were initially eligible for surgery if they had a BMI of 40 kg/m 2 or higher, or a BMI between 35 and 40 kg/m 2 with significant comorbidities according to French guidelines [27]

These findings provide insight into the potential benefits of GLP-1 RAs, but they are preliminary and warrant further investigation
Current as of 6/18/26 Are there any clinical criteria for approval (e.g., BMI level, sustained weight min/max, step therapy such as a weight loss management program)

Topics covered: Share This: You May Also Like Stay in the Know Keep up with all the latest from UC San Diego